SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
Low-calorie diets linked to higher psoriatic arthritis risk, genetic study suggests
While often promoted for health benefits, low-calorie diets may carry hidden inflammatory risks, as genetic evidence reveals a…